| Título: | Alteration Of The K-Ras Gene Expression In Atypical And Nonatypical Hyperplastic Endometrium |
| Autores: |
Izadi-Mood, Narges; Dept. of Pathology, Tehran University of Medical Sciences, Tehran, Iran Sarmadi, Soheila; Dept. of Pathology, Tehran University of Medical Sciences, Tehran, Iran Rostamnasl, Behzad; Dept. of Pathology, Tehran University of Medical Sciences, Tehran, Iran |
| Fecha: | 2013-11-27 |
| Publicador: | Shahid Beheshti University of Medical Sciences |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | Background: Endometrial cancer is the most common gynecologic malignancy that has often proceeded by a premalignant phase. Modern molecular and immune staining methods for precancerous lesions diagnosis have been expanded. One of the genetic alternations in the endometrial cancer carcinogenesis is the mutational activation of the K-ras oncogene. K-ras mutation has recognized to occur at an early stage of neoplastic progression in the endometrium. The purpose of this study is to investigate the expression pattern of K-ras gene in atypical and nonatypic hyperplastic endometrium.Methods: In a prospective study in the referral gynecologic hospital in Tehran, immune histochemical evaluation of K-ras has performed on 72 consecutive specimens in two following groups: endometrial hyperplasia without atypical hyperplastic endometrium (n: 36), and endometrial hyperplasia with atypical hyperplastic endometrium (n: 36). Staining of cells has evaluated in arbitrary quantitative methods in regards to both slides area staining and intensity of color reaction.Results: K-ras immunoreactivity has seen in 3/36 (8.3%) cases of nonatypical hyperplasia and in 2/36 (5.6%) cases of atypical hyperplasia (P: 0.64).Conclusion: We have not establish any significant differences in K-ras expression between the atypical and nonatypical hyperplastic endometrium, and our data has supported this view that K-ras mutation is a very rare event in human endometrial carcinogenesis.Keywords: K-ras; Endometrial cancer; Endometrial hyperplasia; ImmunohistochemistryPlease cite this article as: Izadi-Mood N, Sarmadi S, Rostamnasl B. Alteration of the K-Ras Gene Expression in Atypical and Nonatypical Hyperplastic Endometrium. Iran J Cancer Prev. 2013;6(4):209-13.References1.Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J of Clin Oncol. 2006; 24(29):4783-91.2. Liu F. Molecular carcinogenesis of endometrial cancer. Taiwanese J Obstet Gynecol. 2007; 46(1):26-32.3.Fujiwara K, Enomoto T, Fujita M, Kanda T, Fujiti S, Ito K, et al. Alternation of the K-ras and p53 genes in tamoxifen-associated endometrial carcinoma. Oncol Reports. 2008; 19:1293-98.4.Mutter LG. Histopathology of genetically defined endometrial precancers. Inter J Gynecol Pathol. 2000; 19(4):301-9.5. Sammoud S, Khiari M, Semeh A, Amine L, Ines C, Amira A, et al. Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia.Appl Immunohistochem Mol Morphol. 2012; 20(2):146-52.6.Doll A, Abdal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. The J of Steroid Biol & Molecul Biol. 2008; 108(3-5):221-9.7.Semczuk A, Schneider-Stock R, Berbec H, Marzec B, Jakowicki JA, Roessner A. K-ras exon 2 point mutations in human endometrial cancer. Cancer Lett. 2001; 164(2):207-12.8. Lax SF, Kendall B, Tashiro H, Siebos RJC, Ellenson LH. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer. 2000; 88(4):814-24.9. Hachisuga T, Miyakawa T, Tsjioka H, Emoto M, Kawarabayashi T. K-ras mutation in tamoxifen-related endometrial polyps. Cancer. 2003; 98(9):1890-7.10. Elsabah MT, Adel I. Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J Egypt Natl Canc Inst. 2013; 25(1):51-6.11. Mutter GL, Ince TA, Baak JPA, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Research. 2001; 61(11):4311-14.12. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia. Cancer. 2006; 106(4):804-811.13. Mutter GL, Wada H, Faquin WC, Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. J Clin Pathol. 1999; 52(5):257-62.14. Athanassiaadou P, Athanassiades P, Grapsa D, Gonidi M, Athanassiaadou AM, Stamati PN, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunohistochemical study. Int J Gynecol Cancer. 2007; 17(3):697-704.15. Ikeda T, Yoshinaga K, Suzuki A, Sakurada A, Ohmori H, Horii A. Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol Rep. 2000; 7(3):567-70.16. Matias-Guiu X, Catasus L, Bussagila E, Lagarda H, Garcia A, Pons C, et al. Molecular pathology of endometrial hyperplasia and carcinoma .Human Pathol. 2001; 32(6): 569-77.17. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res.1991; 51(19): 5308-14.18. Sun H, Enomoto T, Shroyer KR, Ozaki K, Fujita M, Ueda Y, et al. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia . Diagn Mol Pathol. 2002; 11(4):204-11.19. Swisher EM, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer.1999; 85(1):119-26.20. Koul A, Willén R, Bendahl PO, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicates alternate modes of tumorigenesis. Cancer.2002; 94(9): 2369-79. |
| Idioma: | Inglés |
1 Health and Education - 2 por Akbari, Mohammad Esmaeil | 6 Effectiveness of Mindfulness-Based Cognitive Therapy on Reduction of Depression and Anxiety Symptoms in Mothers of Children With Cancer por Mehranfar, Mojtaba; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Younesi, Jalal; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Banihashem, Abdollah; Dept. of Internal Medicine and Paediatrics, University of
Medical Sciences, Mashhad, Iran |
2 The Study of DNA Methylation of bax Gene Promoter in Breast and Colorectal Carcinoma Cell Lines por Alipour, Mohsen; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Zargar, Seyed Jalal; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Safarian, Shahrokh; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Fouladdel, Shamile; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran,Azizi, Ebrahim; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran,Jafargholizadeh, Naser; Dept. of Cell & Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran | 7 Prevention and Management of Mucositis in Patients With Cancer: a Review Article por [wlia, ّatemeh; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,«azemeini, ُeidkazem; Burn hospital, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,gholami, neda; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran |
3 Cancer Prevention; Cancer Risk Management por Akbari, Mohammad Esmaeil | 8 Psychosocial Care for Breast Cancer: Physicians' Perspective por Kaviani, Ahmad; Department of surgery, Tehran University of Medical Sciences, Tehran, Iran,Mehrdad, N; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Yunesian, M; school of Public Health , Environmental Research Center, Tehran University of Medical Sciences, Tehran, Iran,Shakiba, B; Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran,Ebrahimi, M; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Majidzadeh, K; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
4 Euthanasia in Cancer Patients, Islamic Point of View por Mousavi, SM; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, A; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Najd Sepas, H; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | 9 Cell Survival Entropy and Cellular Resistance Activation Dose: Effect of Calprotectin on Gastric Adenocarcinoma Cell Line por Rezaei-Tavirani, Mostafa,Rahmati-Roodsari, Mohammad,Mirzaie, Mehdi,Amini Geram, Pooneh,Sobhi, Sara |
5 Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer por Saeidi Saedi, H,Seilanian Toosi, M,Mirsadraei, M,Roodbari, S | 10 Antiphospholipid Antibodies in Neoplastic Patients por Mortazavizadeh, MR,Sadeghmanesh, R |